TWEAK, human recombinant protein
APO3L, DR3LG, TWEAK, TNFSF12
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | O43508 |
|---|---|
| Calculated MW | 17.0 kDa |
| Gene ID | 8742 |
|---|---|
| Gene Symbol | TNFSF12 |
| Other Names | APO3L, DR3LG, TWEAK, TNFSF12 |
| Gene Source | Human |
| Source | E. coli |
| Assay&Purity | SDS-PAGE; ≥98% |
| Assay2&Purity2 | HPLC; ≥98% |
| Recombinant | Yes |
| Results | <10 ng/ml. |
| Target/Specificity | TWEAK |
| Application Notes | Reconstitute in 10 mM Sodium Phosphate (pH 7.5) to a concentration of 1 mg/ml. This solution can then be diluted into other aqueous buffers |
| Format | Lyophilized protein |
| Storage | -20°C; Sterile filtered and lyophilized from 10 mM Sodium Phosphate, pH 7.5 + 0.1 M L-Arg. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Human TWEAK is a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. TWEAK, like many other members of the TNF family, is able to induce interleukin-8 synthesis in a number of cell lines. The recombinant human TWEAK is a 17.0 kDa protein, comprising the TNF-like extraCellular domain of TWEAK
References
Chicheportiche Y.,et al.J. Biol. Chem. 272:32401-32410(1997).
Marsters S.A.,et al.Curr. Biol. 8:525-528(1998).
Pradet-Balade B.,et al.EMBO J. 21:5711-5720(2002).
Clark H.F.,et al.Genome Res. 13:2265-2270(2003).
Zody M.C.,et al.Nature 440:1045-1049(2006).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.

